At present, pathologic stage is the most important indicator for adjuvant chemotherapy after pulmonary resection for lung AD.
However, the most important outcome, as regards adjuvant treatment, is TTP, as after disease recurrence, patients will usually go on to receive other treatments, which may influence OS data.
Currently, tumour stage at diagnosis is the most important prognostic factor and adjuvant chemotherapy is recommended for all patients with stage III disease to reduce the relative risk of recurrence with approximately 30%.
The pathological stage (ypTN) after preoperative treatment (most patients had chemoradiotherapy to 45 50 Gy) was most important, although the use of adjuvant chemotherapy gave some additional value to the models.
Perhaps the most important consideration for deciding what adjuvant to use in a vaccine is what type of CD4+ T cell response is required to direct the ensuing ideal immune response.
One of the most important issues in future research on adjuvant (H IPEC is the selection of patients.
It is the philosophy of the Group that large trials of adjuvant therapy are most important in terms of translating the maximum clinical benefit to the greatest number of patients with breast cancer.
Since the intrinsic or acquired resistance of cancer cells to these agents is the most important cause of the failure of adjuvant chemotherapy, identification of molecules associated with the resistance of tumours to anticancer drugs can provide valuable information in adjuvant chemotherapy of gastric cancer.
The presence of lymph node metastases in CRC patients is the most important prognostic factor and an indication for adjuvant chemotherapy.
Radical resection without rupture is the standard therapy and the most important prognostic tool [46], but whether lymphadenectomy or adjuvant chemotherapy provide benefit is still controversial [11, 12, 19, 21, 27, 29, 31, 36].
